Pricing in Life Sciences
Positioning value at the centre
As pressure applied by payers remains strong on price of healthcare products, industry leaders have identified new opportunities to protect their margin through better differentiation of offering and management of margin leakages.
In this year’s edition of its yearly Pricing survey, Deloitte in Switzerland has asked EMEA Pricing, Market Access, Finance, IT and General Management representatives of leading Life Sciences players about their views on pricing-related opportunities to respond to industry challenges.
The Deloitte Life Sciences Pricing study in EMEA highlights commercial models developed by industry leaders to continue to finance the delivery of value to patients, as well as the implications in terms of capabilities and governance.